The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported. The primary endpoint of a 20% response on the ...

The Food and Drug Administration has approved secukinumab (Cosentyx) for the treatment of active nonradiographic axial spondyloarthritis (nr-axSpA), according to an announcement from the drug’s ...

Cosentyx ® (secukinumab) has received positive advice from the Scottish Medicines Consortium for the treatment of active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with ...

Credit: Getty Images. The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis. Novartis announced results from a phase 3b ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Subcutaneous secukinumab in doses of 300 mg and 150 mg ...

MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on ...

Secukinumab (Cosentyx) showed promise as a steroid-sparing agent in giant cell arteritis, a researcher reported here. In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cosentyx® (secukinumab), a fully human interleukin-17A (IL-17A) inhibitor, is recommended by NICE for adults with non-radiographic axial spondyloarthritis (nr-axSpA) 1, adding to its existing ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...